We performed this audit study at St. Thomas’ Hospital and where I was an observer, and since we know that up to 60% of patients treated with the monoclonal antibodies may not have a brilliant response to this drug, we wonder whether switching them to a ligand anti-CGRP monoclonal antibody could improve their response. And we perform this in clinical practice. So we decided to observe the result of this switch...
We performed this audit study at St. Thomas’ Hospital and where I was an observer, and since we know that up to 60% of patients treated with the monoclonal antibodies may not have a brilliant response to this drug, we wonder whether switching them to a ligand anti-CGRP monoclonal antibody could improve their response. And we perform this in clinical practice. So we decided to observe the result of this switch. And we saw that up to 30% of our patients actually were responders to fremanezumab even if they didn’t respond brilliantly to erenumab.
About implications, we can think for the future to use a ligand anti-CGRP monoclonal antibody for patients that could be considered as refractory. So that didn’t respond also to a monoclonal antibody directed to the receptor. And this could be another option in an otherwise refractory group of patients.